United Therapeutics Corporation (UTHR)Healthcare | Drug Manufacturers - Specialty & Generic | Silver Spring, United States | NasdaqGS
535.57 USD
-11.49
(-2.100%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:46 a.m. EDT
United Therapeutics represents a high-quality business facing a growth headwind. The company boasts exceptional profitability with 40% profit margins and a 20% return on equity, backed by a fortress balance sheet and substantial cash reserves. However, the top-line is contracting with negative revenue and earnings growth, which prevents it from achieving the exceptional status required for a top-tier long-term rating. Short-term momentum is currently muted, trading below its 50-day average despite holding above the 200-day support, while insider selling adds a layer of caution. Options activity suggests a bullish bias with heavy call open interest at strikes significantly above the current price, yet the lack of a dividend yield limits its appeal for income-focused investors. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.043468 |
| AutoARIMA | 0.044440 |
| MSTL | 0.053717 |
| AutoTheta | 0.076395 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 8.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.176 |
| Excess Kurtosis | -0.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 72.123 |
| Market Cap | 22,733,197,312 |
| Trailing P/E | 19.81 |
| Forward P/E | 16.21 |
| Beta | 0.58 |
| Profit Margins | 40.62% |
| Website | https://www.unither.com |
As of July 11, 2026, 2:46 a.m. EDT: Speculators are positioning for upside potential with heavy call open interest concentrated at strikes significantly above the current price, particularly at the 620 and 660 levels. Conversely, put volume is elevated at lower strikes, indicating hedging activity or downside protection rather than pure bearish bets. Implied volatility remains elevated around 48%, reflecting uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8377452 |
| Address1 | 1,000 Spring Street |
| All Time High | 609.35 |
| All Time Low | 4.275 |
| Ask | 534.93 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 470,090 |
| Average Daily Volume3 Month | 486,459 |
| Average Volume | 486,459 |
| Average Volume10Days | 470,090 |
| Beta | 0.58 |
| Bid | 545.52 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 139.982 |
| City | Silver Spring |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 535.57 |
| Current Ratio | 4.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 543.05 |
| Day Low | 530.09 |
| Display Name | United Therapeutics |
| Earnings Call Timestamp End | 1,778,072,400 |
| Earnings Call Timestamp Start | 1,778,072,400 |
| Earnings Growth | -0.122 |
| Earnings Quarterly Growth | -0.147 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | 1,548,499,968 |
| Ebitda Margins | 0.48852003 |
| Enterprise To Ebitda | 13.29 |
| Enterprise To Revenue | 6.492 |
| Enterprise Value | 20,579,495,936 |
| Eps Current Year | 27.35575 |
| Eps Forward | 33.04444 |
| Eps Trailing Twelve Months | 27.03 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 557.9374 |
| Fifty Day Average Change | -22.36737 |
| Fifty Day Average Change Percent | -0.04008939 |
| Fifty Two Week Change Percent | 83.77452 |
| Fifty Two Week High | 609.35 |
| Fifty Two Week High Change | -73.77997 |
| Fifty Two Week High Change Percent | -0.121079795 |
| Fifty Two Week Low | 272.12 |
| Fifty Two Week Low Change | 263.45 |
| Fifty Two Week Low Change Percent | 0.9681391 |
| Fifty Two Week Range | 272.12 - 609.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 929,626,200,000 |
| Float Shares | 38,921,107 |
| Forward Eps | 33.04444 |
| Forward P E | 16.207567 |
| Free Cashflow | 566,412,480 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,400 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.86583 |
| Gross Profits | 2,744,499,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.020380002 |
| Held Percent Institutions | 1.01913 |
| Implied Shares Outstanding | 42,446,733 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,253,664,000 |
| Last Split Factor | 2:1 |
| Long Business Summary | United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. |
| Long Name | United Therapeutics Corporation |
| Market | us_market |
| Market Cap | 22,733,197,312 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36018 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 1,287,399,936 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 23,220,909,754 |
| Number Of Analyst Opinions | 13 |
| Open | 540.105 |
| Operating Cashflow | 1,563,299,968 |
| Operating Margins | 0.41689 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.22 |
| Phone | 301 608 9292 |
| Previous Close | 547.06 |
| Price Eps Current Year | 19.577969 |
| Price Hint | 2 |
| Price To Book | 3.825992 |
| Price To Sales Trailing12 Months | 7.1718082 |
| Profit Margins | 0.40615 |
| Quick Ratio | 4.116 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -11.49 |
| Regular Market Change Percent | -2.10032 |
| Regular Market Day High | 543.05 |
| Regular Market Day Low | 530.09 |
| Regular Market Day Range | 530.09 - 543.05 |
| Regular Market Open | 540.105 |
| Regular Market Previous Close | 547.06 |
| Regular Market Price | 535.57 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 277,409 |
| Return On Assets | 0.12624 |
| Return On Equity | 0.20261 |
| Revenue Growth | -0.016 |
| Revenue Per Share | 72.123 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 42,446,733 |
| Shares Percent Shares Out | 0.0499 |
| Shares Short | 2,117,787 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,191,540 |
| Short Name | United Therapeutics Corporation |
| Short Percent Of Float | 0.0584 |
| Short Ratio | 3.62 |
| Source Interval | 15 |
| State | MD |
| Symbol | UTHR |
| Target High Price | 750.0 |
| Target Low Price | 516.0 |
| Target Mean Price | 663.46155 |
| Target Median Price | 685.0 |
| Total Cash | 2,153,700,096 |
| Total Cash Per Share | 50.739 |
| Total Debt | 0 |
| Total Revenue | 3,169,799,936 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 27.03 |
| Trailing P E | 19.81391 |
| Trailing Peg Ratio | 2.2213 |
| Triggerable | 1 |
| Two Hundred Day Average | 507.7172 |
| Two Hundred Day Average Change | 27.852814 |
| Two Hundred Day Average Change Percent | 0.054858916 |
| Type Disp | Equity |
| Volume | 277,409 |
| Website | https://www.unither.com |
| Zip | 20,910 |